Clinical decision support to aid dyslipidemia therapies for cardiovascular disease
AssigneeElucid Bioimaging Inc.
InventorsAndrew J. Buckler, Ulf Hedin, Ljubica Matic, Matthew Phillips
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and systems for making patient-specific therapy recommendations of a lipid-lowering therapy for patients with known or suspected cardiovascular disease, such as atherosclerosis.
Claims52
-29. (canceled)
A computer-implemented method comprising:
- receiving non-invasively obtained data related to a plaque from a patient;
- inputting the non-invasively obtained data from the patient to an estimation model;
- generating, as an output of the estimation model, virtual 'omics data that include estimated pathway activations or molecule levels, or both, of the patient by applying the estimation model to the non-invasively obtained data from the patient;
- updating an in silico systems biology model using the generated virtual 'omics data to generate an in silico patient-specific systems biology model, wherein
- (i) the in silico systems biology model comprises a set of networks, wherein each network comprises a plurality of nodes, each node representing a baseline level of a molecule or pathway, and a plurality of edges between pairs of nodes, each edge representing a node-node interaction,
- (ii) at least two of the nodes of the plurality of nodes in each network represent molecules or pathways whose levels are affected by an atherosclerotic cardiovascular disease, and
- (iii) at least one network of the set of networks includes a disease-associated pathway activation or molecule level, or both, for each of the nodes in the network;
- perturbing the in silico patient-specific systems biology model to simulate, for the patient, an effect of a dyslipidemia management agent;
- and
- providing an output indicating a level of improvement in the atherosclerotic cardiovascular disease for the patient and a recommendation supporting a clinical decision as to whether the dyslipidemia management agent would benefit the patient.
A system comprising:
- a memory configured to store instructions;
- and
- one or more processors configured to execute the instructions to perform operations comprising:
- inputting, to an estimation model, non-invasively obtained data related to a plaque from a patient;
- generating virtual 'omics data that include estimated pathway activations or molecule levels, or both, of the patient, by applying the estimation model to the non-invasively obtained data from the patient;
- updating an in silico systems biology model using the generated virtual 'omics data to generate an in silico patient-specific systems biology model, wherein
- (i) the in silico systems biology model comprises a set of networks, wherein each network comprises a plurality of nodes, each node representing a baseline level of a molecule or pathway, and a plurality of edges between pairs of nodes, each edge representing a node-node interaction,
- (ii) at least two of the nodes of the plurality of nodes in each network represent molecules or pathways whose levels are affected by an atherosclerotic cardiovascular disease, and
- (iii) at least one network of the set of networks includes a disease-associated pathway activation or molecule level, or both, for each of the nodes in the network;
- perturbing the in silico patient-specific systems biology model to simulate, for the patient, an effect of a dyslipidemia management agent;
- and
- providing an output indicating a level of improvement in the atherosclerotic cardiovascular disease for the patient and a recommendation supporting a clinical decision as to whether the dyslipidemia management agent would benefit the patient.
The system of claim 54, wherein the at least one network of the set of networks further comprises edges representing protein-protein interactions, gene-gene interactions, gene-transcript interactions, transcript-protein interactions, protein-metabolite interactions, and/or protein-gene interactions.
The system of claim 55, wherein interactions represent any one of translation, activation, inhibition, indirect effect, state change, binding, dissociation, phosphorylation, dephosphorylation, glycosylation, ubiquitination, and methylation as a result of an interaction between two molecules.
One or more non-transitory computer-readable media storing instructions that are executable by one or more processing devices, and upon such execution cause the one or more processing devices to perform operations comprising:
- inputting, to an estimation model, non-invasively obtained data related to a plaque from a patient;
- generating virtual 'omics data that include estimated pathway activations or molecule levels, or both, of the patient by applying the estimation model to the non-invasively obtained data from the patient;
- updating an in silico systems biology model using the generated virtual 'omics data to generate an in silico patient-specific systems biology model, wherein
- (i) the in silico systems biology model comprises a set of networks, wherein each network comprises a plurality of nodes, each node representing a baseline level of a molecule or pathway, and a plurality of edges between pairs of nodes, each edge representing a node-node interaction,
- (ii) at least two of the nodes of the plurality of nodes in each network represent proteins whose levels are affected by an atherosclerotic cardiovascular disease, and
- (iii) at least one network of the set of networks includes a disease-associated pathway activation or molecule level, or both, for each of the nodes in the network;
- perturbing the in silico patient-specific systems biology model to simulate, for the patient, an effect of a dyslipidemia management agent;
- and
- providing an output indicating a level of improvement in the atherosclerotic cardiovascular disease for the patient and a recommendation supporting a clinical decision as to whether the dyslipidemia management agent would benefit the patient.
Dependencies are inferred from the claim text.